Cargando…

Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency – analysis from the German Registry

BACKGROUND: Alpha-1-antitrypsin deficiency (AATD) is a rare hereditary disease that is associated with a higher risk to develop chronic obstructive pulmonary disease and liver cirrhosis. Previous cross-sectional studies on AATD individuals have shown a relationship between worse St George’s Respirat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernhard, Nikolas, Lepper, Philipp M, Vogelmeier, Claus, Seibert, Martina, Wagenpfeil, Stefan, Bals, Robert, Fähndrich, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439990/ https://www.ncbi.nlm.nih.gov/pubmed/28553095 http://dx.doi.org/10.2147/COPD.S130925

Ejemplares similares

Cardiovascular risk in patients with alpha-1-antitrypsin deficiency
por: Fähndrich, Sebastian, et al.
Publicado: (2017)

Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology
por: Veith, Martina, et al.
Publicado: (2019)

The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD/Emphysema, Asthma and Bronchiectasis
por: Veith, Martina, et al.
Publicado: (2020)

Therapeutic Application of Alpha-1 Antitrypsin in COVID-19
por: Ritzmann, Felix, et al.
Publicado: (2021)

Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
por: Greulich, Timm, et al.
Publicado: (2016)

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)

Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients
por: Karl, Florian M., et al.
Publicado: (2017)

The effect of exacerbations on lung density in α(1)-antitrypsin deficiency
por: Strange, Charlie, et al.
Publicado: (2023)

Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency
por: Greulich, Timm, et al.
Publicado: (2018)

Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD
por: Zhumagaliyeva, Ardak, et al.
Publicado: (2017)

Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency
por: Lara, Beatriz, et al.
Publicado: (2007)

Augmentation therapy with human alpha-1-proteinase inhibitor reduces exacerbations in patient with bronchiectasis and alpha-1-antitrypsin deficiency
por: Buck, Emanuel, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on well-being and quality of life of patients with alpha-1-antitrypsin deficiency
por: Werdecker, Catherina, et al.
Publicado: (2023)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD
por: Vijayasaratha, Kesavaperumal, et al.
Publicado: (2012)

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach
por: Kahnert, Kathrin, et al.
Publicado: (2018)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2022)

Knockdown of Alpha-1 Antitrypsin with antisense oligonucleotide does not exacerbate smoke induced lung injury
por: Stearns, Kyle, et al.
Publicado: (2021)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

Therapy with Plasma Purified Alpha1-Antitrypsin (Prolastin(®)) Induces Time-Dependent Changes in Plasma Levels of MMP-9 and MPO
por: Koepke, Janine, et al.
Publicado: (2015)

Prevalence of alpha-1 antitrypsin deficiency and allele frequency in patients with COPD in Brazil
por: Russo, Rodrigo, et al.
Publicado: (2016)

Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic
por: Herth, Felix J F, et al.
Publicado: (2021)

Exacerbations of COPD
por: Viniol, Christian, et al.
Publicado: (2018)

Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2023)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry
por: Meischl, Tobias, et al.
Publicado: (2023)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Structural characterization and conformational dynamics of alpha-1 antitrypsin pathogenic variants causing alpha-1-antitrypsin deficiency
por: Shaik, Noor Ahmad, et al.
Publicado: (2022)

Genotypic Frequencies of Mutations Associated with Alpha-1 Antitrypsin Deficiency in Unrelated Bone Marrow Donors from the Murcia Region Donor Registry in the Southeast of Spain
por: Cuenca, Irene, et al.
Publicado: (2023)

IgE is associated with exacerbations and lung function decline in COPD
por: Lommatzsch, Marek, et al.
Publicado: (2022)

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry
por: Rahaghi, Franck F, et al.
Publicado: (2020)

Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency
por: Koczulla, A-Rembert, et al.
Publicado: (2012)

Alpha 1-antitrypsin and survival in hepatocellular carcinoma.
por: Tzonou, A., et al.
Publicado: (1990)

alpha1-Antitrypsin deficiency and hepatocellular cancer.
por: Kew, M. C., et al.
Publicado: (1978)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Alpha 1-antitrypsin retention in an ectopic liver
por: Dettmer, Matthias, et al.
Publicado: (2011)

Polymorphism of alpha-1-antitrypsin in hematological malignancies
por: Topic, Aleksandra, et al.
Publicado: (2009)

Alpha-1-Antitrypsin in Pathogenesis of Hepatocellular Carcinoma
por: Topic, Aleksandra, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fe8dkoibmueufvbdh16gu3tbbf